All In Biotech

Drug Trial Radar · NCT03375320

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 298 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

298

Actual

Start

Oct 26, 2018

Primary completion

Aug 23, 2023

Study completion Sep 1, 2027

Sponsor

Sponsor type
NIH
First posted
Dec 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

Conditions

  • Functioning Pancreatic Neuroendocrine Tumor
  • Intermediate Grade Lung Neuroendocrine Neoplasm
  • Locally Advanced Digestive System Neuroendocrine Neoplasm
  • Locally Advanced Digestive System Neuroendocrine Tumor G1
  • Locally Advanced Lung Neuroendocrine Neoplasm
  • Locally Advanced Pancreatic Neuroendocrine Tumor
  • Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
  • Low Grade Lung Neuroendocrine Neoplasm
  • Lung Neuroendocrine Tumor
  • Lung Neuroendocrine Tumor G2
  • Metastatic Digestive System Neuroendocrine Neoplasm
  • Metastatic Digestive System Neuroendocrine Tumor G1
  • Metastatic Lung Neuroendocrine Neoplasm
  • Metastatic Lung Neuroendocrine Tumor
  • Metastatic Pancreatic Neuroendocrine Neoplasm
  • Metastatic Pancreatic Neuroendocrine Tumor
  • Metastatic Thymus Neuroendocrine Neoplasm
  • Neuroendocrine Neoplasm
  • Neuroendocrine Tumor
  • Neuroendocrine Tumor G2
  • Non-Functioning Pancreatic Neuroendocrine Tumor
  • Pancreatic Serotonin-Producing Neuroendocrine Tumor
  • Thymus Neuroendocrine Tumor
  • Unresectable Digestive System Neuroendocrine Neoplasm
  • Unresectable Digestive System Neuroendocrine Tumor G1
  • Unresectable Lung Neuroendocrine Neoplasm
  • Unresectable Pancreatic Neuroendocrine Neoplasm
  • Unresectable Thymus Neuroendocrine Neoplasm

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood and urine sample collection

  • Cabozantinib S-malateDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Placebo AdministrationOther

    Given PO

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • X-Ray ImagingProcedure

    Undergo x-ray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: 36 months

Locations

432 sites in 1 country. Site status is shown where the registry gives one.

  • Katmai Oncology Group

    Anchorage, Alaska

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Epic Care-Dublin

    Dublin, California

  • Epic Care Partners in Cancer Care

    Emeryville, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Kaiser Permanente-Fresno

    Fresno, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Memorial Medical Center

    Modesto, California

  • Kaiser Permanente-Modesto

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Alta Bates Summit Medical Center - Summit Campus

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Kaiser Permanente-Redwood City

    Redwood City, California

  • Kaiser Permanente-Richmond

    Richmond, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Kaiser Permanente Downtown Commons

    Sacramento, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Kaiser Permanente-South Sacramento

    Sacramento, California

  • Salinas Valley Memorial

    Salinas, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • Kaiser Permanente-San Francisco

    San Francisco, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California

  • Kaiser Permanente San Leandro

    San Leandro, California

Showing 40 of 432 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.